Israel Will Soon Mass Produce Antibody Neutrolizing COVID-19

With every passing day, with COVID-19 haunting our planet, scientists are racing to find a method to eliminate the virus causing the pandemic.

The Institute for Biological Research in Israel has revealed that they have finally achieved a significant breakthrough in the journey to tackle the COVID-19 pandemic.

Naftali Bennett, the country’s Defence Minister stated that the institute had developed a monoclonal neutralizing antibody that could neutralize the virus inside the patient’s body.

According to the Director of the Institute for Biological Research, Shmuel Shapira, the researchers are patenting the antibody formula. Once the patent process is complete, the institute will find an international manufacturer to mass-produce the antibody.

Since the pandemic broke out, the institute has been in charge of the search for treatment and vaccines for the SARS-CoV-2 virus. One of the methods is testing the blood from recovered COVID-19 patients.

From the blood samples, the researchers have extracted antibodies that basically are the proteins that are left in the immune system after getting rid of the SARs-CoV-2 virus in the body. This method is considered to be potential in developing a cure for the disease.

The antibody from IIBR is monoclonal, which means, it was from one single recovered cell. This means it is way more powerful and holds a lot of value in delivering a positive result.

The other kind tested by other researchers globally is called polyclonal, which means, it is from two or more cells.

MigVax, another research team in Israel, has also said that they are reaching the first phase of COVID-19 vaccine development. The team announced that it has received an investment of $12 from OurCrowd to continue the development.

The news agency ANSA from Italy also reports that a firm named Takis from the country has successfully developed the fist COVID-19 vaccine with antibodies generated in mice. The news agency claims that the vaccine would work on humans.

Explaining the process of developing the antibody, Luigi Auriscchi, Takis' CEO says that the antibodies developed by the experimental mice can prevent the virus from harming human cells. Of course, these potential vaccines are raising hope during this time of crisis even when WHO warns that there may never be a 100% foolproof COVID-19 vaccine, just like dengue and HIV.

>>> Israel Is Using Placenta To Treat Critical COVID-19 Patients And It’s Working